34th week of 2013 patent applcation highlights part 50 |
Patent application number | Title | Published |
20130217669 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: | 2013-08-22 |
20130217670 | QUINOXALINE DERIVATIVES - Compounds of the formula I in which R, R | 2013-08-22 |
20130217671 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME - The present invention directs a compound represented by formula (I). | 2013-08-22 |
20130217672 | (+)-3-HYDROXYMORPHINAN-BASED POLYCYCLE DERIVATIVES - A (+)-3-hydroxymorphinan-based polycycle derivative of formula (I) is effective as a neuroprotective agent for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and ischemic stroke. | 2013-08-22 |
20130217673 | MIXED MONOAMINE REUPTAKE INHIBITOR IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of mixed monoamine reuptake inhibitor locally at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least thirty days. In some embodiments, the relief can be for at least at least fifty days, at least one hundred days, at least one hundred and twenty days, at least one hundred and thirty, at least one hundred fifty days or at least one hundred and eighty days. | 2013-08-22 |
20130217674 | SHIP1 MODULATORS AND RELATED METHODS - Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R | 2013-08-22 |
20130217675 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE - This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-08-22 |
20130217676 | 5HT2C RECEPTOR MODULATORS - The present invention relates to novel compounds of Formula (I): | 2013-08-22 |
20130217677 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE - The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions whose use includes the treatment of obesity. | 2013-08-22 |
20130217678 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND - The present invention provides a pharmaceutical agent that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the pharmaceutical agent of the invention comprising as an active ingredient a quinolone compound represented by Formula (1): | 2013-08-22 |
20130217679 | Compositions and Methods for Treatment of Neurodegenerative Disease - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 2013-08-22 |
20130217680 | Inhibitors of the Renal Outer Medullary Potassium Channel - This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure. | 2013-08-22 |
20130217681 | METHOD AND COMPOSITION FOR WEIGHT-GAIN MANAGEMENT - Presented herein is a methodology for reducing weight in obese subjects and in patients receiving various medical treatments that are accompanied with weight gain. The methodology allows for management of weight gain, management of triglyceride levels and weight reduction in obese subjects. | 2013-08-22 |
20130217682 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME - Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: | 2013-08-22 |
20130217683 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF - The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. | 2013-08-22 |
20130217684 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are biaryl benzoimidazole derivatives. They have an inhibitory effect on calcium influx in HEK cells, thereby showing a powerful antagonistic effect on a vanilloid receptor, and further have an analgesic effect, thereby being useful for preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, stroke, bladder hypersensitivity, irritable bowel syndrome, a respiratory disorder such as cough, asthma, and chronic obstructive pulmonary disease, burning, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases. | 2013-08-22 |
20130217685 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR - The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders. | 2013-08-22 |
20130217686 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF - A novel methylcyclohexane derivative, and a pharmaceutical composition including the same that is effective for the prevention or treatment of pain. | 2013-08-22 |
20130217687 | ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition. | 2013-08-22 |
20130217688 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2013-08-22 |
20130217689 | HETEROARYLS AND USES THEREOF - This invention provides compounds of formula I: | 2013-08-22 |
20130217690 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | 2013-08-22 |
20130217691 | Compositions and Methods for Treating Hyperproliferative Disorders - A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-increasing retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) compounds selected from the groups consisting of (i) a non-18 carbon chain length L-threo-sphinganine(s) or pharmaceuticeutically acceptable salt thereof, (ii) glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor(s), and (iii) sphingomyelin or dihydrosphingomyelin synthase inhibitor(s). Preferred L-threo-sphinganines are of carbon chain length 17 carbons, 19 carbons and 20 carbons. A preferred glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingomyelin or dihydrosphingomyelin synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred hyperproliferative disorder is brain cancers. | 2013-08-22 |
20130217692 | CYCLIC AMIDE DERIVATIVE - Provided is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A is C | 2013-08-22 |
20130217693 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV - The invention relates to a compound of Formulae I and/or II: | 2013-08-22 |
20130217694 | METHOD OF REDUCING THE SEVERITY OF INFLAMMATORY DERMATOLOGICAL CONDITIONS - The present invention provides a method of reducing the severity of one or more symptoms of an inflammatory dermatological condition in a subject, comprising topically administering to the skin of a subject in need of such reduction an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. | 2013-08-22 |
20130217695 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2013-08-22 |
20130217697 | ORAL PHARMACEUTICAL FILM FORMULATION FOR BITTER TASTING DRUGS - The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agent(s). | 2013-08-22 |
20130217698 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO- [2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF - This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same. | 2013-08-22 |
20130217699 | PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS - Provided are dihydroisoxazole compounds I useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling parasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. Also provided are compounds and processes useful for making the dihydroisoxazole compounds. | 2013-08-22 |
20130217700 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - Pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT | 2013-08-22 |
20130217701 | COMPOSITIONS OF AZIMILIDE DIHYDROCHLORIDE - The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof. | 2013-08-22 |
20130217702 | INDOLE DERIVATIVES - The present invention relates to the indole derivatives of formula (I), wherein R | 2013-08-22 |
20130217703 | SUSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF - The present invention relates to a method of antagonizing a 5-HT | 2013-08-22 |
20130217704 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 - Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes. | 2013-08-22 |
20130217705 | NAPHTHYRIDINE DERIVATIVE - The present invention provides, for example, the following compound: | 2013-08-22 |
20130217706 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease; and other diseases. | 2013-08-22 |
20130217707 | TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER WITH NHE INHIBITORS - The present invention relates to a method of treating attention deficit hyperactivity disorder in a subject. This method includes selecting a subject with attention deficit hyperactivity disorder and administering to the selected subject a sodium/hydrogen exchanger inhibitor under conditions effective to treat the subject for attention deficit hyperactivity disorder. Methods of identifying compounds suitable to treat attention deficit hyperactivity disorder are also disclosed. | 2013-08-22 |
20130217708 | MEGLUMINE SALT OF 6-FLUORO-3-HYDROXY-2-PYRAZINE CARBOXAMIDE - A preparation replete with a meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide has superior solubility, and is useful as a preparation for injection. | 2013-08-22 |
20130217709 | Cyclic Amine Azaheterocyclic Carboxamides - The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 2013-08-22 |
20130217710 | METHODS FOR TREATING CANCER - Methods are provided for treating a human having cancer comprising detecting at least one mutation in a Ras protein or a gene encoding at least one Ras protein from at least one tumor cell from said human and treating said human having at least one mutation in at least one Ras protein or a gene encoding at least one Ras protein with a pharmaceutical composition comprising at least one MEK inhibitor comprising a compound of Structure (I): | 2013-08-22 |
20130217711 | Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease - The invention comprises use of a therapeutically effective amount of the compound of the formula below for preparation of a medicament for treating polycystic kidney diseases (PKD) in a mammal, such as human or feline (e.g., Persian cat).Formula (I). Also provided are the above compound and compositions comprising it for treating PKD. | 2013-08-22 |
20130217712 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients. | 2013-08-22 |
20130217713 | PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients. | 2013-08-22 |
20130217714 | Non-Flushing Niacin Analogues, and Methods of Use Thereof - One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels. | 2013-08-22 |
20130217715 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS - Substituted pyrazolophenyl-benzenesulfonamide compounds of formula (I) are described, wherein m, R1, R2, R3, and R4 are defined in the description, which modulate the activity of protein kinases, These compounds find utility in treating diseases caused by deregulated protein kinase activity, such as cancer and cell proliferative disorders. | 2013-08-22 |
20130217716 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2013-08-22 |
20130217717 | COMPOUND USEFUL FOR THE TREATMENT OF NONSENSE-MUTATION-MEDIATED DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND - The present invention relates to the compound of formula (I) | 2013-08-22 |
20130217718 | TREATMENT OF PROGRESSIVE NEURODEGERATIVE DISEASE WITH IBUDILAST - Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine). | 2013-08-22 |
20130217719 | Combination of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 2013-08-22 |
20130217720 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR 2 MODULATORS - The present invention relates to novel imidazolidine-2,4-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2 (FPR2). | 2013-08-22 |
20130217721 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF B-RAF INHIBITOR-RESISTANT MELANOMAS - Specific, targetable molecules mediating acquired resistance of B-RAF-mutant melanomas to a B-RAF inhibitor, thereby providing materials and methods for the treatment and detection of B-RAF inhibitor resistant cancers, such as melanoma. A method of identifying a patient to be treated with an alternative to B-RAF inhibitor therapy is described. Also described is a method of treating a patient having cancer. The patient is administered a MEK inhibitor, optionally in conjunction with vemurafenib therapy, or an inhibitor of the MAPK pathway (RAF, MEK, ERK) in conjunction with an inhibitor of the RTK-PI3K-AKT-mTOR pathway. | 2013-08-22 |
20130217722 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - A novel imidazolopyridine according to Formula I, able to inhibit JAK as disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. | 2013-08-22 |
20130217723 | Pharmaceutical Composition Combining Tenatoprazole and an Anti-Inflammatory Agent - The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations. | 2013-08-22 |
20130217724 | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARB- OXAMIDE, PREPARATION AND USES THEREOF - The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof. | 2013-08-22 |
20130217725 | Macrocyclic Inhibitors Of Hepatitis C Virus - Inhibitors of HCV replication of formula (I) | 2013-08-22 |
20130217726 | INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS AND USES THEREOF - The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions. | 2013-08-22 |
20130217727 | 1-(HETEROCYCLIC CARBONYL)-2-SUBSTITUTED PYRROLIDINES - The present invention relates to fungicidal 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. | 2013-08-22 |
20130217728 | NEW CCR2 ANTAGONISTS - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (Ia) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. | 2013-08-22 |
20130217729 | PIPERIDINE SULPHONAMIDE DERIVATIVES - The present invention relates to piperidine sulphonamide derivatives of formula | 2013-08-22 |
20130217730 | POLYSUBSTITUTED BENZOFURANS AND MEDICINAL APPLICATIONS THEREOF - The present invention refers to compounds of formula (I): | 2013-08-22 |
20130217731 | CD38 AND OBESITY - This document provides methods and materials relating to obesity. For example, methods and materials related to treating obesity and identifying agents having the ability to treat obesity are provided. | 2013-08-22 |
20130217732 | Selective Androgen Receptor Modulators - This invention provides compounds of formula I, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same. | 2013-08-22 |
20130217733 | ACYLBENZENE DERIVATIVE - Provided are compounds having an excellent hypoglycemic action and a β cell- or pancreas-protecting action or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed. | 2013-08-22 |
20130217734 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA - A compound represented by the following general formula (II) or a salt thereof is used as an activator of PPARδ. | 2013-08-22 |
20130217735 | FUNGICIDAL COMPOSITIONS AND METHODS OF USE - Disclosed are compositions and methods of preparing compositions of active fungicidal ingredients. Also disclosed are methods of using the compositions described herein to improve fungicide penetration into the plant tissue, reduce fungicide volatility and drift, decrease water solubility of the fungicides, and introduce additional biological function to fungicides. | 2013-08-22 |
20130217736 | Naphthalene Isoxazoline Invertebrate Pest Control Agents - Disclosed are compounds of Formula 1, | 2013-08-22 |
20130217737 | Use of Malononitrilamides in Neuropathic Pain - Provided herein are compounds and pharmaceutical compositions for use in the treatment of neuropathic pain and the neuropathic pain syndromes. | 2013-08-22 |
20130217738 | Methods and Assays for Detecting and Treating Hypoglycemia - Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for treating hypoglycemia. The methods are useful for treating diabetes mellitus and screening drug candidates for potential efficacy. | 2013-08-22 |
20130217739 | THERAPEUTIC COMPOUNDS - Disclosed herein is a compound having a structure | 2013-08-22 |
20130217740 | METRONIDAZOLE ESTERS FOR TREATING ROSACEA - A compound of formula (I): | 2013-08-22 |
20130217741 | TOPICAL PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SKIN DAMAGE - A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided. | 2013-08-22 |
20130217742 | Methods and Compositions for Increasing Solubility of Azole Drug Compounds that are Poorly Soluble in Water - The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid. | 2013-08-22 |
20130217743 | CANCER PREVENTION AND TREATMENT METHODS BASED ON DIETARY POLYAMINE CONTENT - Controlling exogenous polyamines may be used, in some aspects, as an adjunctive strategy to chemoprevention with polyamine inhibitory agents, for example, anti-carcinoma combination therapies comprising ornithine decarboxylase (ODC) inhibitor and a spermidine/spermine N | 2013-08-22 |
20130217744 | EFFICACY IN TREATING BACTERIAL INFECTIONS - The present disclosure relates to molecules which function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as | 2013-08-22 |
20130217745 | FUNGICIDAL COMPOSITIONS - A method of controlling phytopathogenic diseases on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a combination of components (A) and (B) in a synergistically effective amount, wherein component (A) is a compound of formula (I) compound of formula (I) wherein R is hydrogen or methoxy; Q is (Q | 2013-08-22 |
20130217746 | AGROCHEMICAL CONCENTRATES COMPRISING ALKOXYLATED ADJUVANTS - The present invention relates to methods of reducing the viscosity of an aqueous agrochemical concentrate comprising a) an adjuvant selected from an alkoxylated aliphatic acid, an alkoxylated aliphatic alcohol, an alkoxylated aliphatic amide and an alkoxylated aliphatic amine, wherein the concentration of adjuvant in the aqueous agrochemical concentrate is at least 50 g/l; the method comprising including b) a compound selected from: i. an aryl sulphonate; ii. an aliphatic mono alcohol; iii. an aliphatic polyol comprising at least four contiguous carbon atoms; and iv. anaryl alcohol; in the aqueous agrochemical concentrate; wherein the aqueous agrochemical concentrate comprises an agrochemical active ingredient. The invention also relates to the agrochemical con centrates and methods of using the agrochemical concentrates for controlling or preventing infestation of plants by phytopathogenic microorganisms. | 2013-08-22 |
20130217747 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME - Methods of using certain a-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects. | 2013-08-22 |
20130217748 | COSMETIC CLEANING AGENT - A cosmetic cleaning agent, comprises: in a cosmetic carrier: (a) greater than or equal to 12 wt % of a surfactant mixture comprising (i) at least one anionic surfactant and (ii) at least one zwitterionic/amphoteric surfactant in a weight ratio (i):(ii) of (2,5-3,5):1; (b) at least one cationic copolymer comprising (meth)acrylamide and dialkyldiallylammonium salts as the monomers; and (c) at least one opacifier and/or one pearlizer; wherein the quantities are based on the total weight of the cleaning agent. A method of producing a stable turbid and/or pearlescent cosmetic cleaning agent comprises: combining (a) at least one anionic surfactant and (b) at least one zwitterionic and/or an amphoteric surfactant to produce a surfactant combination; and combining, at room temperature, the surfactant combination with, (c) at least one cationic copolymer comprising (meth)acrylamide and dialkyldiallylammonium salts as the monomers, and (d) at least one opacifier and/or one pearlizer. | 2013-08-22 |
20130217749 | MODULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE-MITCHONDRIAL (PEPCK-M) EXPRESSION - Provided herein are methods, compounds, and compositions for reducing expression of phosphoenolpyruvate carboxykinase-mitochondrial (PEPCK-M) mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preventing or decreasing diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and/or hypertriglyceridemia in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and/or hypertriglyceridemia, or a symptom thereof. | 2013-08-22 |
20130217750 | Cell Growth Inhibitor and Screening Method Thereof - An object is to provide a cell growth inhibitor also effective for androgen-independent prostate cancer. The present invention provides a cell growth inhibitor having, as an active ingredient, an expression inhibitor or function inhibitor of PSF. | 2013-08-22 |
20130217751 | POLYNUCLEOTIDES FOR REDUCING RESPIRATORY SYNCYTIAL VIRUS GENE EXPRESSION - This invention pertains to polynucleotides, such as small interfering RNA (siRNA), useful for reducing the expression of respiratory syncytial virus (RSV) genes within a subject; and methods for treating a patient suffering from, or at risk of developing, an RSV infection by administering such polynucleotides to the subject. | 2013-08-22 |
20130217752 | METHOD OF DERIVING MATURE HEPATOCYTES FROM HUMAN EMBRYONIC STEM CELLS - A method for producing mature hepatocytes having functional hepatic enzyme activity from human pluripotent cells is disclosed. The method includes the step of transferring an external vector comprising the DNA sequence coding for a microRNA having the seed sequence of the microRNA miR-122, the DNA sequence coding for a microRNA having the seed sequence of the microRNA miR-let-7c, a microRNA having the seed sequence of the microRNA miR-122, a microRNA having the seed sequence of the microRNA miR-let-7c, or a combination thereof into one or more fetal hepatocytes. The resulting cells differentiate into mature hepatocytes that exhibit functional hepatic enzyme activity, and can be used in drug metabolism and toxicity testing, in the study of viruses that target hepatic tissue, and as therapeutics. | 2013-08-22 |
20130217753 | AMPHIPHILIC MACROMOLECULES FOR NUCLEIC ACID DELIVERY - The invention provides amphiphilic macromolecules that are useful for delivering nucleic acids to cells and that are useful as delivery agents for gene therapy. | 2013-08-22 |
20130217754 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS - Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1. | 2013-08-22 |
20130217755 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 2013-08-22 |
20130217756 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression. | 2013-08-22 |
20130217758 | MULTIANTIVIRUS COMPOUND, COMPOSITION AND METHOD FOR TREATMENT OF VIRUS DISEASES - A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus. | 2013-08-22 |
20130217759 | Sulphonamine Compounds and Methods of Making and Using Same - The invention provides sulphonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 2013-08-22 |
20130217760 | METHOD FOR ENHANCING THERAPEUTIC EFFECT OF ANTICANCER THERAPIES - Disclosed is a method for enhancing therapeutic effect of anticancer therapies for an animal, comprising administering one or more dibenzo-p-dioxin derivative in an effective amount to the animal in anticancer therapies. The method augments therapeutic effects of an anticancer therapies, with the suppression of side effects of the anticancer therapies. | 2013-08-22 |
20130217761 | Pharmaceutical Composition Comprising Cinchonains Ia and Ib, Process For Preparing An Epimeric Mixture of Cinchonains Ia and Ib, Use and Method for Reverting/Combating Ventricular Fibrillation - The present invention relates to the effects of the epimeric mixture of cinchonains Ia and Ib on pathologies that involve alterations in the cardiovascular system, in combating, preventing and reverting ventricular fibrillation in human beings and animals, especially for combating spontaneous or electric-stimulus-induced ventricular fibrillation, to revert spontaneous or electric-stimulus-induced ventricular fibrillations, for preventing ventricular fibrillation, for the treatment of ventricular fibrillation of any etiology or for the treatment of post-fibrillation to maintain normal cardiac rhythm. The present invention further relates to methods for the synthesis of an epimeric mixture of the chemical substances cinchonain Ia and Ib. The present invention also relates to the use of these chemical substances in reverting/combating ventricular fibrillation and/or in protecting against ventricular fibrillation. A pharmaceutical composition will be used for administering these chemical substances in human beings and animals. | 2013-08-22 |
20130217762 | Selective Androgen Receptor Modulators - The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof. | 2013-08-22 |
20130217763 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 2013-08-22 |
20130217764 | PERIPHERALLY RESTRICTED FAAH INHIBITORS - Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R | 2013-08-22 |
20130217765 | MULTIFUNCTIONAL NANOCONJUGATES AND USES THEREOF - The present invention provides multifunctional nanoconjugates and methods of using them to destroy biological and chemical agents. The nanoconjugates include a dye-coated metal oxide nanoparticles conjugated to a substance capable of binding specifically or non-specifically to an agent. Specifically, the nanoconjugates can be photoactivated by visible light to degrade and destroy biological agents, such as but not limited to bacteria and viruses. | 2013-08-22 |
20130217766 | FORMULATIONS FOR CATHEPSIN K INHIBITORS - The instant invention relates to pharmaceutical compositions containing cathespin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions. | 2013-08-22 |
20130217767 | Cosmetic Composition - The present invention concerns a cosmetic composition comprising the following fluorinated analog of prostaglandin F2α: The cosmetic composition may further comprise a complexing agent and/or a humectant. The present invention further relates to a cosmetic kit, comprising the cosmetic composition and an applicator for application thereof. | 2013-08-22 |
20130217768 | SIMPLE PROCESS TO PRODUCE AND SEPARATE WATER SOLUBLE AND OIL SOLUBLE ANTIOXIDATIVE FLAVORING COMPOSITIONS FROM LABIATAE HERBS USING GREEN SOLVENTS - Processes for preparing water soluble and oil soluble antioxidant compositions extracted together from Labiatae herbs in a single extraction using an alcohol and water solvent, followed by a simple, yet effective purification step that allows the separation of the water soluble antioxidative fractions containing mainly rosmarinic acid from antioxidative fractions containing mainly carnosic acid and carnosol, without cumbersome acid/base partitioning steps. | 2013-08-22 |
20130217769 | PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle | 2013-08-22 |
20130217770 | METHOD FOR TREATING IRRITABLE BOWEL SYNDROME BY ADMINISTRATION OF CHLORIDE CHANNEL OPENER - A chloride channel opener, especially a prostaglandin compound, is used for the treatment of functional gastrointestinal disorders. The prostaglandin compound can be, for example, a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E | 2013-08-22 |